









市场行情
/
股票
/
nasdaq-slno
/

Soleno Therapeutics Inc

SLNO

49.550USD

-0.220-0.44%

收盘 11/26, 16:00（美东）报价延迟15分钟

2.26B总市值

亏损市盈率 TTM



Soleno Therapeutics Inc

49.550

-0.220-0.44%

概览公司财务分析

概览

公司

财务

分析

关于 Soleno Therapeutics Inc 公司

Soleno Therapeutics, Inc. 是一家临床阶段的生物制药公司。该公司专注于开发和商业化用于治疗罕见疾病的新型疗法。其主要候选药物二氮嗪胆碱缓释片 (DCCR) 是一种缓释片，是一种用于治疗普拉德-威利综合征 (PWS) 的每日一次口服药，最近完成了其第 3 阶段开发计划。DCCR 是一种有效的 ATP 敏感钾 (KATP) 通道激活剂。DCCR 片剂含有活性成分二氮嗪胆碱，二氮嗪是一种苯并噻二嗪类药物的胆碱盐。DCCR 的作用模式是针对大脑、胰腺和脂肪组织，有可能影响 PWS 等复杂疾病，以减少食欲、减少食物寻求、提高饱腹感、改善胰岛素和瘦素抵抗并减少体脂。该公司在美国和欧盟拥有 PWS 中 DCCR 的快速通道称号以及该药物的孤儿药称号。

Soleno Therapeutics Inc简介



公司代码SLNO

公司名称Soleno Therapeutics Inc

上市日期Oct 23, 2014

CEODr. Anish Bhatnagar, M.D.

员工数量92

证券类型Ordinary Share

年结日Oct 23

公司地址100 Marine Parkway, Suite 400

城市REDWOOD CITY

上市交易所NASDAQ Capital Market Consolidated

国家United States of America

邮编94065

电话16502138444

网址https://soleno.life/

公司代码SLNO

上市日期Oct 23, 2014

CEODr. Anish Bhatnagar, M.D.

Soleno Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. James H. (Jim) Mackaness

Chief Financial Officer

90.68K

+32.66%

Dr. Michael Huang, M.D.

Senior Vice President - Clinical Development

36.82K

-11.07%

Ms. Kristen Yen

Senior Vice President - Global Clinical Operations and Patient Advocacy

28.14K

-66.09%

Ms. Dawn Carter Bir

Independent Director

16.99K

+30.70%

Mr. William G. (Bill) Harris

Independent Director

12.89K

+44.84%

Dr. Birgitte Volck, M.D., Ph.D.

Independent Director

11.04K

+56.65%

Dr. Andrew Sinclair, Ph.D.

Independent Director

10.49K

+61.40%

Mr. Mark W. Hahn, CPA

Independent Director

10.05K

Ms. Patricia C. Hirano

Vice President - Regulatory Affairs

6.81K

-36.00%

Dr. Anish Bhatnagar, M.D.

Chairman of the Board, Chief Executive Officer

名称

名称/职务

职务

持股

持股变动

Mr. James H. (Jim) Mackaness

Chief Financial Officer

90.68K

+32.66%

Dr. Michael Huang, M.D.

Senior Vice President - Clinical Development

36.82K

-11.07%

Ms. Kristen Yen

Senior Vice President - Global Clinical Operations and Patient Advocacy

28.14K

-66.09%

Ms. Dawn Carter Bir

Independent Director

16.99K

+30.70%

Mr. William G. (Bill) Harris

Independent Director

12.89K

+44.84%

Dr. Birgitte Volck, M.D., Ph.D.

Independent Director

11.04K

+56.65%

收入明细

FY2025Q2

由于公司未披露，未能获取相关数据

地区USD

名称

营收

占比

United States

32.66M

0.00%

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

Fidelity Management & Research Company LLC

12.15%

Janus Henderson Investors

11.28%

T. Rowe Price Associates, Inc.

7.16%

BlackRock Institutional Trust Company, N.A.

5.47%

The Vanguard Group, Inc.

5.21%

其他

58.73%

持股股东

占比

Fidelity Management & Research Company LLC

12.15%

Janus Henderson Investors

11.28%

T. Rowe Price Associates, Inc.

7.16%

BlackRock Institutional Trust Company, N.A.

5.47%

The Vanguard Group, Inc.

5.21%

其他

58.73%

股东类型

持股股东

占比

Investment Advisor

49.52%

Investment Advisor/Hedge Fund

44.44%

Hedge Fund

22.96%

Venture Capital

5.33%

Individual Investor

1.87%

Research Firm

1.50%

Bank and Trust

0.71%

Pension Fund

0.34%

Sovereign Wealth Fund

0.11%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

416

58.51M

108.94%

-3.11M

2025Q2

384

58.69M

110.44%

+1.14M

2025Q1

373

57.15M

113.59%

-442.82K

2024Q4

313

53.26M

117.76%

+3.04M

2024Q3

277

49.14M

121.09%

-377.00K

2024Q2

234

44.76M

117.95%

+4.14M

2024Q1

189

36.54M

114.10%

-1.05M

2023Q4

146

32.09M

102.81%

+3.37M

2023Q3

107

21.08M

166.08%

+14.34M

2023Q2

5.70M

63.31%

-1.46M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Fidelity Management & Research Company LLC

3.23M

6.07%

+1.10M

+52.00%

Jun 30, 2025

Janus Henderson Investors

5.31M

9.99%

+167.11K

+3.25%

Jun 30, 2025

T. Rowe Price Associates, Inc.

3.42M

6.43%

+1.05M

+44.45%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

2.51M

4.72%

+791.68K

+46.16%

Jun 30, 2025

The Vanguard Group, Inc.

2.48M

4.67%

+619.99K

+33.33%

Jun 30, 2025

Avoro Capital Advisors LLC

2.05M

3.86%

-475.00K

-18.81%

Jun 30, 2025

Wellington Management Company, LLP

621.04K

1.17%

-72.61K

-10.47%

Jun 30, 2025

Vivo Capital, LLC

3.96M

7.45%

Aug 01, 2025

State Street Investment Management (US)

1.40M

2.64%

+235.78K

+20.17%

Jun 30, 2025

持股ETF



更新时间: 11月6日周四

机构名称

占比

SPDR S&P Biotech ETF

1.61%

Direxion Daily S&P Biotech Bull 3X Shares

0.84%

JPMorgan Healthcare Leaders ETF

0.72%

Harbor Health Care ETF

0.68%

Virtus LifeSci Biotech Clinical Trials ETF

0.61%

VictoryShares US Small Mid Cap Value Momentum ETF

0.2%

T Rowe Price Small-Mid Cap ETF

0.18%

iShares Russell 2000 Growth ETF

0.17%

JPMorgan BetaBuilders US Small Cap Equity ETF

0.17%

Fidelity Fundamental Small-Mid Cap ETF

0.16%

SPDR S&P Biotech ETF

占比1.61%

Direxion Daily S&P Biotech Bull 3X Shares

占比0.84%

JPMorgan Healthcare Leaders ETF

占比0.72%

Harbor Health Care ETF

占比0.68%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.61%

VictoryShares US Small Mid Cap Value Momentum ETF

占比0.2%

T Rowe Price Small-Mid Cap ETF

占比0.18%

iShares Russell 2000 Growth ETF

占比0.17%

JPMorgan BetaBuilders US Small Cap Equity ETF

占比0.17%

Fidelity Fundamental Small-Mid Cap ETF

占比0.16%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

Aug 25, 2022

Merger

15→1

Aug 25, 2022

Merger

15→1

Aug 25, 2022

Merger

15→1

Aug 25, 2022

Merger

15→1

公告日期

类型

比率

Aug 25, 2022

Merger

15→1

Aug 25, 2022

Merger

15→1

Aug 25, 2022

Merger

15→1

Aug 25, 2022

Merger

15→1

常见问题

Soleno Therapeutics Inc的前五大股东是谁？



Soleno Therapeutics Inc 的前五大股东如下：
Fidelity Management & Research Company LLC持有股份：3.23M，占总股份比例：6.07%。
Janus Henderson Investors持有股份：5.31M，占总股份比例：9.99%。
T. Rowe Price Associates, Inc.持有股份：3.42M，占总股份比例：6.43%。
BlackRock Institutional Trust Company, N.A.持有股份：2.51M，占总股份比例：4.72%。
The Vanguard Group, Inc.持有股份：2.48M，占总股份比例：4.67%。